MYELOFIBROSIS
Clinical trials for MYELOFIBROSIS explained in plain language.
Never miss a new study
Get alerted when new MYELOFIBROSIS trials appear
Sign up with your email to follow new studies for MYELOFIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Myelofibrosis drug combo trial halted early
Disease control TerminatedThis study tested whether adding the drug parsaclisib to the standard treatment ruxolitinib could help people with myelofibrosis, a rare bone marrow cancer. It included 252 adults with an enlarged spleen and symptoms. The trial was terminated early, so final results are not avail…
Matched conditions: MYELOFIBROSIS
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated May 17, 2026 05:27 UTC
-
Promising combo study halted early: hope for advanced blood cancer patients
Disease control TerminatedThis study tested a combination of two drugs, ruxolitinib and CPX-351, in people with advanced myeloproliferative neoplasms (MPN), a type of blood cancer that has progressed. The goal was to find the best dose and see if the combination worked better than CPX-351 alone. Only 12 p…
Matched conditions: MYELOFIBROSIS
Phase: PHASE1, PHASE2 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
Myelofibrosis drug combo trial halted midway
Disease control TerminatedThis study tested whether adding the experimental drug parsaclisib to the standard drug ruxolitinib could help people with myelofibrosis whose spleens were still enlarged and symptoms remained despite ruxolitinib alone. The trial enrolled 177 adults and compared the combination a…
Matched conditions: MYELOFIBROSIS
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
Myelofibrosis drug combo trial halted early – what we know
Disease control TerminatedThis study tested a combination of two experimental drugs, TQ05105 and TQB3909, in 21 adults with moderate- to high-risk myelofibrosis, a rare bone marrow disorder. The goal was to find the safest dose and see if the combo could shrink an enlarged spleen by at least 35% after 24 …
Matched conditions: MYELOFIBROSIS
Phase: PHASE1, PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated May 14, 2026 12:04 UTC